Skip to main content
Top
Published in: Surgery Today 5/2021

01-05-2021 | Metastasis | Original Article

Criteria for liver resection for metastasis from bile duct cancer

Authors: Shintaro Yamazaki, Tadatoshi Takayama, Yusuke Mitsuka, Nao Yoshida, Tokio Higaki

Published in: Surgery Today | Issue 5/2021

Login to get access

Abstract

Background

The surgical indications for liver metastasis from bile duct cancer remain contentious, because surgery is generally thought unlikely to improve survival. However, recent reports show that long-term survival has been achieved with liver resection of metastasis from recurrent bile duct cancer in selected patients.

Methods

Liver resection for liver metastasis from bile duct cancer was proposed only when the following criteria were met: liver-only metastasis, a solitary tumor, and no increase in the number of lesions during 3 months of observation. This study aimed to validate our criteria and to analyze which factors impact on survival.

Result

Between 2003 and 2017, 164 patients underwent pathologically curative resection for bile duct cancer. Recurrence developed in 98 of these patients, as liver-only metastasis in 25. Eleven of these 25 patients underwent liver resection (liver resection group), and 14 did not (non-liver resection group). The median overall survival was longer in the liver resection group than in all the patients (44 months vs. 17.8 months, respectively p = 0.040). The median overall survival was better in the liver resection group than in the non-liver resection group (44 months vs. 19.9 months, p = 0.012). The disease-free interval was also significantly longer in the liver resection group than in the non-liver resection group [22 months (range; 4–34 months) vs. 3 months (2–11), p < 0.001].

Conclusion

Potentially, metachronous solitary liver metastasis from bile duct cancer is an indication for liver resection when the patient has had a long disease-free interval. Observation for 3 months from first detection of metastasis may optimize the selection for this surgery.
Literature
1.
go back to reference Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484–92.CrossRef Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484–92.CrossRef
2.
go back to reference De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252:142–8.CrossRef De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252:142–8.CrossRef
3.
go back to reference Wellner UF, Shen Y, Keck T, Jin WY, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47:271–9.CrossRef Wellner UF, Shen Y, Keck T, Jin WY, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47:271–9.CrossRef
4.
go back to reference Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.CrossRef Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.CrossRef
5.
go back to reference Koerkamp BG, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch ORC, et al. Recurrence rate and pattern of Perihilar Cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041–9.CrossRef Koerkamp BG, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch ORC, et al. Recurrence rate and pattern of Perihilar Cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041–9.CrossRef
6.
go back to reference Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732–8.CrossRef Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732–8.CrossRef
7.
go back to reference Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y, et al. Predictive factors of early recurrence in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. Gastroenterol Res Pract. 2018;3(2018):6431254. Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y, et al. Predictive factors of early recurrence in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. Gastroenterol Res Pract. 2018;3(2018):6431254.
8.
go back to reference Malka D, Cervera P, Foulon S, Trarbach T, Fouchardière C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819–28.CrossRef Malka D, Cervera P, Foulon S, Trarbach T, Fouchardière C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819–28.CrossRef
9.
go back to reference Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121:3290–7.CrossRef Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121:3290–7.CrossRef
10.
go back to reference Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116:561–7.CrossRef Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116:561–7.CrossRef
11.
go back to reference Hayashibe A, Kameyama M. Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. HPB. 2008;10:144–7.CrossRef Hayashibe A, Kameyama M. Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. HPB. 2008;10:144–7.CrossRef
12.
go back to reference Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607–13.CrossRef Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607–13.CrossRef
13.
go back to reference Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, De Jong MC, et al. Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. J Am Coll Surg. 2012;214:769–77.CrossRef Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, De Jong MC, et al. Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. J Am Coll Surg. 2012;214:769–77.CrossRef
14.
go back to reference Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426–33.CrossRef Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426–33.CrossRef
15.
go back to reference Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: should we consider resection in selected cases? World J Gastrointest Oncol. 2018;10:211–20.CrossRef Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: should we consider resection in selected cases? World J Gastrointest Oncol. 2018;10:211–20.CrossRef
16.
go back to reference Takao S, Shinchi H, Uchikura K, Kubo M, Aikou T. Liver metastases after curative resection in patients with distal bile duct cancer. Br J Surg. 1999;86:327–31.CrossRef Takao S, Shinchi H, Uchikura K, Kubo M, Aikou T. Liver metastases after curative resection in patients with distal bile duct cancer. Br J Surg. 1999;86:327–31.CrossRef
17.
go back to reference De Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256–63.CrossRef De Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256–63.CrossRef
18.
go back to reference Yamazaki S, Takayama T, Moriguchi M, Mitsuka Y, Okada S, Midorikawa Y, et al. Criteria for drain removal following liver resection. Br J Surg. 2012;99:1584–90.CrossRef Yamazaki S, Takayama T, Moriguchi M, Mitsuka Y, Okada S, Midorikawa Y, et al. Criteria for drain removal following liver resection. Br J Surg. 2012;99:1584–90.CrossRef
19.
go back to reference Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 2008;32:1067–74.CrossRef Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 2008;32:1067–74.CrossRef
Metadata
Title
Criteria for liver resection for metastasis from bile duct cancer
Authors
Shintaro Yamazaki
Tadatoshi Takayama
Yusuke Mitsuka
Nao Yoshida
Tokio Higaki
Publication date
01-05-2021
Publisher
Springer Singapore
Published in
Surgery Today / Issue 5/2021
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02159-4

Other articles of this Issue 5/2021

Surgery Today 5/2021 Go to the issue